Journal profile · Medicine-Oncology
Experimental Hematology & Oncology
ISSN 2162-3619 · BioMed Central · ENGLAND · Founded 2012
Experimental Hematology & Oncology: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 17.56; fully open access; APC about USD 3,390; median 105 days to acceptance (99 articles, last 24 months); 141 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Experimental Hematology & Oncology is published by BioMed Central and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are CAR-T cell therapy research, Acute Myeloid Leukemia Research and Cancer Immunotherapy and Biomarkers, together about 28.1% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editor-in-chief Delong LiuPublisher website
Editorial board by country: 11 in mainland China (about 26%); most named United States 17, Mainland China 11, Germany 4, France 4, Italy 2 (43 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- CAR-T cell therapy researchMedicine12%
- Acute Myeloid Leukemia ResearchMedicine9.4%
- Cancer Immunotherapy and BiomarkersMedicine6.7%
- Lymphoma Diagnosis and TreatmentMedicine6.1%
- Immune Cell Function and InteractionImmunology and Microbiology5.8%
- Immunotherapy and Immune ResponsesImmunology and Microbiology4.9%
- Immune cells in cancerImmunology and Microbiology4.4%
- Multiple Myeloma Research and TreatmentsMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Hematology | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
| Minor | Hematology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCASCurrent ContentsPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 17.56LetPub ·
- Impact factor (publisher) 2025
- 17.5Publisher website ·
- 5-year impact factor (publisher) 2025
- 14.9Publisher website ·
- CiteScore 2026-06
- 19.6LetPub ·
- SJR 2026-06
- 4.13LetPub ·
- SNIP 2026-06
- 2.17LetPub ·
- h-index
- 78OpenAlex ·
- i10-index
- 583OpenAlex ·
- 2-year mean citedness
- 14.01OpenAlex ·
- Self-citation rate
- 5.7%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 92LetPub ·
- Downloads per year (publisher) 2025
- 1,300,000Publisher website ·
Articles by year OpenAlex count · 938 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 100 | 100 | 124 |
| 2025 | 141 | 141 | 2,037 |
| 2024 | 123 | 123 | 2,937 |
| 2023 | 105 | 105 | 3,650 |
| 2022 | 108 | 108 | 3,900 |
| 2021 | 60 | 60 | 2,791 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
105 daysMedian, submission to acceptance · P25–P75 78 days – 173 days
- Acceptance to online
- median 15 days (99 articles)
- Submission to online
- median 130 days
- Sample
- 99 articles with submission and acceptance dates (268 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 6 weeksLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 6 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,990 / USD 3,390 / GBP 2,690 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,290 / EUR 2,890 / GBP 2,590 | — | — | |
| LetPub | GBP 2,490 / USD 3,190 / EUR 2,790 | Yes | — | |
| Publisher website | GBP 2,690 / USD 3,390 / EUR 2,990 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare1 items from the author guidelines
- Suggested reviewers
- Optional
Policy excerpts from the journal's websiteData availability, License & copyright, Open access, Peer review
- Data availability Formatting the 'Availability of data and materials' section of your manuscript
Data availability strongly encouraged or required; deposit in public repositories where appropriate. Model summary
The following format for the 'Availability of data and materials section of your manuscript should be used:
Source ↗Publisher website ·- License & copyright Licensing and copyright
Open access under CC BY-NC-ND or CC BY licences. Model summary
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. Experimental Hematology & Oncology articles are published open access under a CC BY-NC-ND (Creative Commons …
Source ↗Publisher website ·- Open access Benefits of open access
APC waivers/discounts for authors in lowest income countries; case-by-case for others. Model summary
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
Source ↗Publisher website ·- Peer review Peer review policy
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Founded
- 2012
- ISSN
- 2162-3619
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Experimental Hematology & Oncology
What CAS zone is Experimental Hematology & Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Experimental Hematology & Oncology is in Zone 2 of Medicine, and in Zone 2 of the minor category Hematology / Oncology. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Experimental Hematology & Oncology?
The latest impact factor listed by LetPub is 17.56; CiteScore 19.6, h-index 78.
How long does peer review take at Experimental Hematology & Oncology?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 105 days (interquartile range 78–173 days); authors report an average review time of about 6 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Experimental Hematology & Oncology based?
Of the 43 board members whose country the journal's board page names, 11 (about 26%) are in mainland China; the countries named most often are United States (17), Mainland China (11) and Germany (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Experimental Hematology & Oncology?
According to LetPub and DOAJ records, Experimental Hematology & Oncology is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Embase, CAS and Current Contents; that list has not been checked against each database.
Is Experimental Hematology & Oncology open access, and what is the APC?
Experimental Hematology & Oncology is a fully open-access journal. APC about USD 3,390.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .